Your session is about to expire
← Back to Search
NMDA receptor antagonist
Sublingual Micro-Dose Ketamine for Acute Stress Disorder
Phase 4
Waitlist Available
Led By Andre Atoian, MD
Research Sponsored by Limbic Medical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 120 days
Awards & highlights
Study Summary
A retrospective chart review of an open-label trial of low-dose ketamine administered to front-line Healthcare workers who were identified as experiencing acute stress disorder due to the COVID-19 Pandemic.
Eligible Conditions
- Acute Stress Disorder
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 120 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 120 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Patient self-reported outcome measure
Trial Design
1Treatment groups
Experimental Treatment
Group I: Sublingual Micro-Dose KetamineExperimental Treatment1 Intervention
Ketamine micro-dose 37.5mg compounded sublingual daily administration
Find a Location
Who is running the clinical trial?
Enovex PharmacyUNKNOWN
Limbic MedicalLead Sponsor
Andre Atoian, MDPrincipal InvestigatorLimbic Medical
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger